Pharmaceuticals, Biotechnology and Life Sciences
Anavex Life Scienceshas announced late breaking oral communication at CTAD 2019, by presenting the interim 2-Year (104)-Week) data from the Phase 2a ANAVEX®2-73 (blarcamesine) extension study, with Alzheimer’s disease patients followed for up to five years, at the 12th Clinical Trials On Alzheimer’s Disease (CTAD) 2019 Conference in San Diego, CA (December 4-7, 2019).
Anavex has ensured most of the cash for a U.S. multicentre Phase 2 clinical trial of Rett syndrome treatment Anavex2-73.
Anavex is moving forward with the development program for ANAVEX 2-73 for the treatment of Alzheimer’s disease in a…
Anavex has confirmed the information about positive safety and cognitive efficacy data from the Phase 2a Alzheimer’s trial for ANAVEX 2-73.
Anavex Life Sciences Corp, a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS)…